Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 224 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Supratentorial Neoplasms Clear all
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Low-Grade Glioma

NCT00313729
View directory record Official record
Conditions
CNS Tumor, Adult
Interventions
temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

NCT00919750
View directory record Official record
Conditions
Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 18 Years
Enrollment
1,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
163
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

NCT00054756
View directory record Official record
Conditions
Healthy, Pituitary Disease, Thyroid Disease
Interventions
TRH (Thyrotropin Releasing Hormone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors

NCT00003241
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
phenylacetate
Drug
Lead sponsor
Texas Children's Cancer Center
Other
Eligibility
2 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain Tumor

NCT00006342
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma
Interventions
chromosomal translocation analysis, gene rearrangement analysis, mutation analysis
Genetic
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme

NCT00006386
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, radiation therapy, stereotactic radiosurgery
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
217
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 166 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas

NCT00929669
View directory record Official record
Conditions
Gonadotroph Adenomas
Interventions
pasireotide LAR
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

NCT01462695
View directory record Official record
Conditions
Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Infratentorial Ependymoma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma
Interventions
Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
86
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1 Interventional

Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade Gliomas

NCT00003463
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, irinotecan hydrochloride, polifeprosan 20 with carmustine implant, surgical procedure
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Los Angeles, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Study of Tumor Samples From Patients With Ependymoma Treated on the Children's Oncology Group ACNS0121 Trial

NCT01407744
View directory record Official record
Conditions
Childhood Infratentorial Ependymoma, Childhood Supratentorial Ependymoma, Newly Diagnosed Childhood Ependymoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

NCT04042753
View directory record Official record
Conditions
Pituitary, Pituitary Tumor, Pituitary Carcinoma, Pituitary Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

NCT05052957
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Interventions
P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy, temozolomide, Filgrastim, carmustine
Biological · Drug · Radiation
Lead sponsor
Leland Metheny
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Phase 1 Interventional

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

NCT01430351
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 1Phase 2 Interventional

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

NCT00041587
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Mixed Oligoastrocytoma
Interventions
IL13-PE38QQR, targeted fusion protein therapy, surgery
Drug · Procedure
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Denver, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Tamoxifen in Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme

NCT00006388
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
tamoxifen citrate, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Early Phase 1 Interventional

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

NCT07493447
View directory record Official record
Conditions
Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions
Panitumumab-IRDye800
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Active, not recruiting Phase 1 Interventional

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

NCT00102648
View directory record Official record
Conditions
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
Lonafarnib, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Terminated Phase 2 Interventional Results available

Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors

NCT02749227
View directory record Official record
Conditions
Pituitary Tumor, ACTH-producing Pituitary Tumour
Interventions
Pasireotide LAR
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme

NCT00002545
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, low-LET photon therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
243
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 186 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 7, 2026, 2:38 PM EDT
Not listed Phase 2 Interventional

Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma

NCT00283543
View directory record Official record
Conditions
Newly Diagnosed Supratentorial Malignant Glioma
Interventions
Gliadel Wafer, Temozolomide, Limited field radiation
Drug · Procedure
Lead sponsor
Kentuckiana Cancer Institute
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors

NCT00499798
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 7, 2026, 2:38 PM EDT
Recruiting Not applicable Interventional

DDAVP for Pituitary Adenoma

NCT04569591
View directory record Official record
Conditions
Cushing's Disease, Pituitary Adenoma
Interventions
Desmopressin acetate
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 7, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery)

NCT03636568
View directory record Official record
Conditions
Hyponatremia, Hyponatremic, Pituitary Tumor, Pituitary, Surgery
Interventions
Fluid Restricted Group
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Sep 7, 2026, 2:38 PM EDT
Completed No phase listed Observational

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

NCT04369703
View directory record Official record
Conditions
Sellar and Suprasellar Masses, Pituitary Tumor
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 95 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Sep 7, 2026, 2:38 PM EDT